By regulating the influence of sEVs on CD8 + T cells, NK cells, etc., and elucidating sEV-mediated immune evasion mechanisms (such as the transfer of PD-L1 and NKG2D ligands), more potent immunotherapeutic approaches for PCa could be devised. The gene discussed is CD8A; the disease is posterior cortical atrophy.